Gilead's lenacapavir: HIV prospects strongest in long-acting combos with Merck's islatravir [Yahoo! Finance]
Gilead Sciences, Inc. (GILD)
Last gilead sciences, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.gilead.com
Company Research
Source: Yahoo! Finance
Lenacapavir/islatravir combo carries mechanistic rationale Mixed oral/subQ regimens don't provide additional convenience Cabuneva experience highlights appetite for long-acting drugs Gilead Sciences' capsid inhibitor lenacapavir has the most competitive potential in long-acting combination regimens in HIV, including with Merck's islatravir, experts said. Early lenacapavir data indicates a noteworthy viral load reduction in heavily treatment-experienced individuals. But combinations with oral antiretroviral (ARV) regimens are unlikely to push the needle forward for most people living with HIV without the convenience of a single administration method, they added. Lenacapavir and islatravir have elicited expert interest since the long-acting injectable drugs could be given less frequently but still carry high potency. Gilead announced a collaboration with Merck in March to study lenacapavir with islatravir, a nucleoside reverse transcriptase translocation inhibitor (NRTTI), whic
Show less
Read more
Impact Snapshot
Event Time:
GILD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GILD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GILD alerts
High impacting Gilead Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
GILD
News
- High Growth Tech Stocks To Watch This September 2024 [Yahoo! Finance]Yahoo! Finance
- Gilead Sciences (GILD) Stock Sinks As Market Gains: Here's Why [Yahoo! Finance]Yahoo! Finance
- Gilead Sciences, Inc. (NASDAQ: GILD) had its "neutral" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $70.00 price target on the stock.MarketBeat
- Cell Therapy Manufacturing Market Historical Trends (2022-2023) and Forecasted Estimates (2024-2035) [Yahoo! Finance]Yahoo! Finance
- Should You Be Worried About Gilead Sciences, Inc.'s (NASDAQ:GILD) 5.7% Return On Equity? [Yahoo! Finance]Yahoo! Finance
GILD
Earnings
- 8/8/24 - Beat
GILD
Sec Filings
- 9/13/24 - Form 4
- 9/13/24 - Form 4
- 9/12/24 - Form 144
- GILD's page on the SEC website